Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Theratechnologies has discovered a new growth-hormone releasing factor (GRF) peptide and is all set to initiate pre-clinical feasibility trial to evaluate the efficacy of the molecule.
Subscribe to our email newsletter
The GRF peptide is said to have the similar potency and efficacy as that of tesamorelin and is shorter than it.
Tesamorelin is an analogue of the human growth-hormone releasing which reduces excess abdominal fat in HIV-infected patients with lipodystrophy
Theratechnologies vice-resident research Krishna Peri said the discovery of GRF peptides with improved pharmaceutical properties and similar potency and efficacy to tesamorelin gives way to alternative routes of drug delivery.